Abstracts Archive - Page 981 of 2425 - ACR Meeting Abstracts

Abstract Number: 400 • 2019 ACR/ARP Annual Meeting
Performance of the European League Against Rheumatism/American College of Rheumatology Idiopathic Inflammatory Myopathies Classification Criteria in a Myositis Cohort from Argentina
Belén Virasoro¹, Ramiro Gomez ², Dafne Capelusnik ³, Andrea Braillard Poccard ⁴, Emilce Schneeberger ⁵, Silvia Papasidero ⁶, Malena Viola ⁷, Maria de la Vega ⁸, Carolina Costi ⁹, Mercedes Garcia ¹⁰, Cecilia Asnal ¹¹, Ana Cappuccio ¹², Demelza Yucra ¹³, Natalia Tamborenea ¹⁴, Mariano Rivero ¹⁵, Amelia Granel ¹⁶, Linda Vergel Orduz ¹³, Marina Dalpiaz ¹⁴, Juan Bande ⁶, Carolina Segura Escobar ¹⁵ and Cecilia Pisoni ¹⁷, ¹CEMIC, buenos aires, Buenos Aires, Argentina, ²Hospital de Clínicas José de San Martín, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, ³Instituto de Rehabilitacion Psicofisica, CABA, Ciudad Autonoma de Buenos Aires, Argentina, ⁴Hospital de Clínicas José de San Martin, Buenos Aires, Buenos Aires, Argentina, ⁵Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁶Hospital General de Agudos Dr. E. Tornú, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, ⁷Centro Reumatologia DOM, Buenos Aires, Buenos Aires, Argentina, ⁸CEIM Investigaciones Medicas, Buenos Aires, Argentina, ⁹Hospital General “San Martín” de la Plata, La Plata, Buenos Aires, Argentina, ¹⁰Hospital San Martín, La Plata, Argentina, ¹¹Instituto Centenario, Buenos Aires, Buenos Aires, Argentina, ¹²Hospital Francés, Buenos Aires, Buenos Aires, Argentina, ¹³Sanatorio Güemes, Buenos Aires, Buenos Aires, Argentina, ¹⁴Hospital Rivadavia, Buenos Aires, Buenos Aires, Argentina, ¹⁵Hospital Británico, Buenos Aires, Buenos Aires, Argentina, ¹⁶Hospital San Roque,Gonnet,La Plata,Buenos Aires.Argentina, La Plata, Buenos Aires, Argentina, ¹⁷Centro de Educación Médica e Investigaciones Clínicas Norberto Quirno (CEMIC), Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
Background/Purpose: Patients with Idiopathic Inflammatory Myopathies (IIM) have been classified mainly according to Bohan and Peter (B&P) criteria, proposed in 1975. In 2017 the new…
Abstract Number: 401 • 2019 ACR/ARP Annual Meeting
Performance of EULAR/ACR Classification Criteria for Idiopathic Inflammatory Myopathies in a Real-life Cohort of Adult Patients
Ana Campar¹ and Carlos Vasconcelos ², ¹Centro Hospitalar do Porto, Porto, Portugal, ²University of Porto, UMIB Abel Salazar Biomedical Sciences Institute, Porto, Portugal
Background/Purpose: Idiopathic Inflammatory Myopathies (IIM) are rare and heterogenous diseases, remaining a clinical challenge and persisting with high morbidity and mortality. The lack of consensus…
Abstract Number: 402 • 2019 ACR/ARP Annual Meeting
Chronic Disease Course and IVIg-dependance in Long-term Follow-up of Anti-HMGCR Immune-mediated Necrotizing Myopathy
Océane Landon-Cardinal¹, Kuberaka Mariampillai ², Céline Anquetil ³, Aude Rigolet ², Baptiste Hervier ⁴, Nicolas Champtiaux ², Olivier Benveniste ³ and Yves Allenbach ³, ¹Centre Hospitalier de l'Université de Montréal, Montréal, Canada, ²Pitié-Salpêtrière University Hospital, Paris, France, ³Sorbonne Université, Paris, France, ⁴Hopital Pitie-Salpetriere, Paris, France
Background/Purpose: Anti-HMGCR antibodies have been associated with a severe form of immune-mediated necrotizing myopathy (IMNM) with a poor muscle strength recovery and early muscle damage.…
Abstract Number: 403 • 2019 ACR/ARP Annual Meeting
Single-specificity Anti-SMN Autoantibodies Are Associated with a Novel Scleromyositis Overlap Syndrome
Alexandra Baril-Dionne ¹, Océane Landon-Cardinal², Alain Meyer ³, Josiane Bourre-Tessier ¹, Yves Troyanov ⁴, Anne-Marie Mansour ⁵, Farah Zarka ⁵, Jean-Paul Makhzoum ⁶, Jessica Nehme ⁵, Eric Rich ¹, Jean-Richard Goulet ¹, Tamara Grodzicky ¹, Isabelle Richard ⁷, Marie Hudson ⁸, Valérie Leclair ⁹, Ira Targoff ¹⁰, Minoru Satoh ¹¹, Marvin Fritzler ¹² and Jean-Luc Senecal ¹, ¹Centre hospitalier de l'Universite de Montreal, Montreal, QC, Canada, ²Division of Rheumatology, Centre hospitalier de l'Université de Montréal; Department of Medicine, Université de Montréal, Montreal, QC, Canada, ³Centre de Reference des Maladies Autoimmunes Rares, Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ⁴Division of Rheumatology, Department of Medicine, Hôpital du Sacre-Coeur de Montreal, Montreal, QC, Canada, ⁵Hôpital du Sacre-Coeur de Montreal, Montreal, QC, Canada, ⁶Vasculitis Clinic, Hopital du Sacre-Coeur de Montreal, Montreal, QC, Canada, ⁷CISSS AT Rouyn-Noranda, Rouyn-Noranda, QC, Canada, ⁸Jewish General Hospital, Lady Davis Institute for Medical Research, and Department of Medicine, McGill University, Montreal, QC, Canada, ⁹Division of Rheumatology, Department of Medicine, Jewish General Hospital; Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Montreal, QC, Canada, ¹⁰University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹¹Department of Clinical Nursing, School of Health Sciences, University of Occupational and Environmental Health, Kitakyushu, Japan, ¹²Cumming School of Medicine, University of Calgary, Calgary, AB, Canada
Background/Purpose: Autoantibodies (aAbs) to proteins comprising the survival of motor neuron (SMN) macromolecular complex have not been thoroughly studied. Only two publications described clinical associations…
Abstract Number: 404 • 2019 ACR/ARP Annual Meeting
Autoantibody Profiles Delineate Three Distinct Subsets of Scleromyositis
Julie D'Aoust¹, Valérie Leclair ², Geneviève Gyger ³, Alain Meyer ⁴, Marvin Fritzler ⁵, Océane Landon-Cardinal ⁶, Erin O'Ferrall ⁷, Jason Karamchandani ⁷, Benjamin Ellezam ⁸, Rami Massie ⁷, Minoru Satoh ⁹, Yves Troyanov ¹⁰ and Marie Hudson ¹¹, ¹McGill University, Montreal, QC, Canada, ²Division of Rheumatology, Department of Medicine, Jewish General Hospital; Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Montreal, QC, Canada, ³Division of Rheumatology, Department of Medicine, Jewish General Hospital, Montreal, QC, Canada, ⁴Centre de Reference des Maladies Autoimmunes Rares, Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ⁵Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁶Division of Rheumatology, Centre hospitalier de l'Université de Montréal; Department of Medicine, Université de Montréal, Montreal, QC, Canada, ⁷Montreal Neurological Institute, Montreal, QC, Canada, ⁸Centre hospitalier universitaire Sainte-Justine, Montreal, QC, Canada, ⁹Department of Clinical Nursing, School of Health Sciences, University of Occupational and Environmental Health, Kitakyushu, Japan, ¹⁰Division of Rheumatology, Department of Medicine, Hôpital du Sacre-Coeur de Montreal, Montreal, QC, Canada, ¹¹Jewish General Hospital, Lady Davis Institute for Medical Research, and Department of Medicine, McGill University, Montreal, QC, Canada
Background/Purpose: Myopathy is an important cause of morbidity in systemic sclerosis (SSc). Nevertheless, scleromyositis remains incompletely characterized owing at least in part to its clinical…
Abstract Number: 405 • 2019 ACR/ARP Annual Meeting
Anti-MDA5 Dermatomyositis: A Case Series, Systematic Review and Meta-analysis of the Literature
Mohammad Ryadh Pokeerbux¹, Luc Dauchet ², Benjamin Lopez ³, Hélène Maillard ¹, Sandrine Morell-Dubois ¹, Eric Auxenfants ⁴ and Eric Hachulla ⁵, ¹Department of Internal Medicine and Clinical Immunology, CHU Lille, University of Lille, Lille, France, ²Department of Epidemiology, CHU Lille, University of Lille, Lille, France, ³Institute of Immunology, CHU Lille, University of Lille, Lille, France, ⁴Department of Internal Medicine, Roubaix Hospital, Roubaix, France, ⁵Dept. of Internal Medicine and Clinical Immunology, Hôpital Claude Huriez, University of Lille, Lille, France, Lille, France
Background/Purpose: Anti-MDA5 dermatomyositis is characterized by little or no muscle involvement, distinct cutaneous features and an increased risk of severe interstitial lung disease (ILD) with…
Abstract Number: 406 • 2019 ACR/ARP Annual Meeting
Myositis Related Antibodies and Interstitial Lung Disease: Variables Associated with Baseline Lung Function and Functional Improvement: Results from a Multicentric Latin-american Cohort
VERONICA WOLFF¹, MARIA LAURA ALBERTI ², FELIPE REYES ³, ERNESTO JUAREZ ⁴, JORGE ROJAS-SERRANO ⁴, FABIAN CARO ², IVETTE BUENDIA ⁴, MAYRA MEJIA ⁴, MATIAS FLORENZANO ⁵ and FRANCISCO PAULIN ², ¹INSTITUTO NACIONAL DEL TORAX - UNIVERSIDAD DE CHILE, SANTIAGO, Chile, ²HOSPITAL MARIA FERRER, BUENOS AIRES, Argentina, ³HOSPITAL CLINICO UNIVERSIDAD DE CHILE, SANTIAGO, Chile, ⁴INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS DE MEXICO DF, CIUDAD DE MEXICO, Mexico, ⁵INSTITUTO NACIONAL DEL TORAX, SANTIAGO, Chile
Background/Purpose: Idiopathic inflammatory myopathies (IIM) comprise a group of autoimmune diseases associated to different myositis related antibodies (MRA), that determine distinct phenotypes but share some…
Abstract Number: 407 • 2019 ACR/ARP Annual Meeting
Utility of Anti-SSA/SSB Assay and Anti-Ro 52 Antibody Assay in Routine Clinical Practice for Risk Assessment of Patients with Idiopathic Inflammatory Myositis
Galina Marder ¹, Sonali Narain², Maria-Louise Barilla-Labarca ¹ and Ana Valle ¹, ¹Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, ²Northwell Health, Great Neck, Long Island, NY
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are chronic autoimmune diseases affecting multiple organ systems and associated with a diverse autoantibody profile. Anti-SSA/SSB are the most frequent…
Abstract Number: 408 • 2019 ACR/ARP Annual Meeting
Frequency of Concomitant Non-aminoacyl-transfer-RNA Synthetase Autoantibodies in Patients with Antisynthetase Syndrome
Alexis Katz¹, Soumya Chatterjee ² and Yuxuan Jin ³, ¹Cleveland Clinic, Cleveland, OH, ²Cleveland Clinic, Cleveland, ³Quantitative Health Science, Cleveland Clinic, Cleveland, OH
Background/Purpose: Antisynthetase syndrome (ASSD) is an autoimmune disease with features including interstitial lung disease (ILD), myositis, inflammatory arthritis, Raynaud phenomenon, and mechanic’s hands.¹ Eight aminoacyl-transfer-RNA…
Abstract Number: 409 • 2019 ACR/ARP Annual Meeting
Antisynthetase Syndromes: Correlation of Indirect Immunofluorescence Patterns with Diagnosis Criteria Fulfillment
Martín Greco¹, María Jesús García De Yébenes ², Inmaculada Alarcón ³, Iñigo Rua Figueroa ⁴, Estíbaliz Loza ², Carlos Rodriguez-Lozano ⁵, Anahy Brandy-Garcia ⁶ and Loreto Carmona ², ¹Rheumatology Department. Hospital Universitario de Gran Canaria Dr. Negrín., Las Palmas, Spain, ²Instituto de Salud Musculoesquelética - Inmusc., Madrid, Spain, ³Biochemical Department, Autoimmunity Laboratory. Hospital Universitario de Gran Canaria Dr. Negrín., Las Palmas, Canarias, Spain, ⁴Hospital Doctor Negrin, Las Palmas, ⁵Rheumatology Department. Hospital Universitario de Gran Canaria Dr. Negrín., Madrid, Spain, ⁶Hospital Universitari Germans Trias i Pujol, Badalona, Spain
Background/Purpose: The antisynthetase syndromes (ASSD) are characterized by the presence of anti-aminoacyl transfer RNA synthetase (ARS) autoantibodies and a clinical classic triad of myositis, arthritis,…
Abstract Number: 410 • 2019 ACR/ARP Annual Meeting
Prevalence of Malignancy in Myositis Patients with Anti-aminoacyl-tRNA Synthetase Antibodies: A Single Center Retrospective Study and Literature Review
Taiga Kuga¹, Yoshiyuki Abe ², Kurisu Tada ³, Masakazu Matsushita ¹, Ken Yamaji ¹ and Naoto Tamura ¹, ¹Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ²Department of Rheumatology, Juntendo University, Tokyo, Japan, Tokyo, Japan, ³Juntendo University School of Medicine, Tokyo, Japan
Background/Purpose: Anti-aminoacyl-tRNA synthetase antibodies (anti-ARS antibodies) are related to Idiopathic Inflammatory Myopathy (IIM) and Anti-Synthetase Syndrome (ASS). While anti-TIF1-γ antibody and anti-NXP-2 antibody are highly…
Abstract Number: 411 • 2019 ACR/ARP Annual Meeting
Frequency and Staining Patterns of Antinuclear Antibodies in Myositis Patients Without Known Myositis-specific Autoantibodies
Maria casal-Dominguez¹, Iago Pinal-Fernandez ¹, Ana Marin ², Maria Teresa Sanz-Martinez ², Andres Baucells-de la Pena ³, Katherine Pak ⁴, Yuji Hosono ¹, Lisa Christopher-Stine ⁵ and Andrew L Mammen ⁴, ¹NIH, Bethesda, ²Vall d'Hebron Hospital, Barcelona, Spain, ³Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁴National Institutes of Health, Bethesda, ⁵Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Objective:To determine the frequency and staining patterns of antinuclear antibodies (ANA) in myositis patients who do not have known myositis-specific autoantibodies.Methods: Material and methods:Sera…
Abstract Number: 412 • 2019 ACR/ARP Annual Meeting
Elevated Serum BAFF Levels in Patients with Dermatomyositis: Association with Interstitial Lung Disease
Takashi Matsushita¹, Tadahiro Kobayashi ¹, Miyu Kano ¹, Yasuhito Hamaguchi ¹ and Kazuhiko Takehara ², ¹Kanazawa University, Kanazawa, Japan, ²Department of Dermatology, Kanazawa University, Kanazawa, Japan
Background/Purpose: Patients with dermatomyositis (DM) frequently have myositis-specific autoantibodies (MSAs), which are closely associated with different clinical features. Patients with anti-aminoacyl-tRNA synthetase (ARS) antibody (Ab)…
Abstract Number: 413 • 2019 ACR/ARP Annual Meeting
Performance of the Patient Reported Outcomes Measurement Information System 29-item Profile in Comparison to the Clinical Disease Activity Index (CDAI) and Routine Assessment of Patient Index Data 3 (RAPID3) in an Australian Rheumatoid Arthritis Cohort
Kathryn Gibson¹, Dana Gerogevsky ², Frank Huang ³, Ray Fang ³ and Joseph Descallar ⁴, ¹Liverpool Hospital, Sydney, New South Wales, Australia, ²Royal Prince Alfred Hospital, Sydney, Australia, ³University of New South Wales, Sydney, New South Wales, Australia, ⁴Ingham Research Institute, Sydney, New South Wales, Australia
Background/Purpose: The Patient-Reported Outcomes Measurement Information System (PROMIS) was developed to improve measurement of patient-reported outcomes. A large study from the US reported guarded support…
Abstract Number: 414 • 2019 ACR/ARP Annual Meeting
Treat-to-Target Approach in the Management of Elderly Rheumatoid Arthritis Patients
Vivek Joseph ¹, Swetha Vontela ², Surjeet Dheer³, Molly Weinberg ⁴, Zuhayr Haq ² and Arundathi Jayatilleke ⁵, ¹Drexel University, PHILADELPHIA, PA, ²Drexel University, Philadelphia, ³Mercy Catholic Medical Center, Philadelphia, ⁴Drexel University, Philadlephia, ⁵Drexel, Philadelphia, PA
Background/Purpose: With the advent of biologic therapy for RA, the American College of Rheumatology advocates a treat to target (TTT) approach in the treatment of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].